Iranpour Soodabeh, Nejati Vahid, Delirezh Nowruz, Biparva Pouria, Shirian Sadegh
Department of Biology, Faculty of Science, Urmia University, Urmia, Iran.
Department of Cellular and Molecular Biotechnology, Institute of Biotechnology, Urmia University, Urmia, Iran.
J Exp Clin Cancer Res. 2016 Oct 26;35(1):168. doi: 10.1186/s13046-016-0444-6.
Developing safe and effective cancer vaccine formulations is a primary focus in the field of cancer immunotherapy. Dendritic cells (DC) are currently employed as cellular vaccine in clinical trials of tumor immunotherapy. Recognizing the critical role of DCs in initiating anti-tumor immunity has resulted in the development of several strategies that target vaccine antigens to DCs to trigger anti-tumor T cell responses. To increase the efficiency of antigen delivery systems for anti-tumor vaccines, encapsulation of tumor-associated antigens in polymer nanoparticles (NPs) has been established.
In this study, the effect of tumor lysate antigen obtained from three stage III breast cancer tissues encapsulated within PLGA NPs to enhance the DC maturation was investigated. The T-cell immune response activation was then fallowed up. Fresh breast tumors were initially used to generate tumor lysate antigens containing poly lactic-co-glycolic acid (PLGA) NP. The encapsulation efficiency and release kinetics were profiled. The efficiency of encapsulation was measured using Bradford protein assays measuring the dissolved NPs. The stability of released antigen from NPs was verified using SDS-PAGE. To evaluate the hypothesis that NPs enhances antigen presentation, including soluble tumor lysate, tumor lysate containing NPs and control NPs the efficiency of NP-mediated tumor lysate delivery to DCs was evaluated by assessing CD3+ T-cell stimulation after T cell/and DCs co-culture.
The rate of encapsulation was increased by enhancing the antigen concentration of tumor lysate. However, increasing the antigen concentration diminished the encapsulation efficiency. In addition, higher initial protein contenting NPs led to a greater cumulative release. All three patients released variable amounts of IFN-γ, IL-10, IL-12 and IL-4 in response to re-stimulation. T cells stimulated with lysate-pulsed DCs induced a substantial increase in IFN-γ and IL-12 production. We demonstrated that NPs containing tumor lysate can induce maturation and activation of DCs, as antigen alone does.
PLGA-NPs are attractive vehicles for protein antigen delivery which effectively induce stimulation and maturation of DCs, allowing not only an enhanced antigen processing and immunogenicity or improved antigen stability, but also the targeted delivery and slow release of antigens.
开发安全有效的癌症疫苗制剂是癌症免疫治疗领域的主要研究重点。树突状细胞(DC)目前在肿瘤免疫治疗的临床试验中用作细胞疫苗。认识到DC在启动抗肿瘤免疫中的关键作用,已促使人们开发了多种将疫苗抗原靶向DC以触发抗肿瘤T细胞反应的策略。为了提高抗肿瘤疫苗抗原递送系统的效率,已将肿瘤相关抗原封装在聚合物纳米颗粒(NP)中。
在本研究中,研究了封装在聚乳酸-乙醇酸共聚物(PLGA)纳米颗粒中的来自三期乳腺癌组织的肿瘤裂解物抗原增强DC成熟的效果。随后追踪T细胞免疫反应的激活情况。最初使用新鲜乳腺肿瘤来生成含有聚乳酸-乙醇酸共聚物(PLGA)纳米颗粒的肿瘤裂解物抗原。对包封效率和释放动力学进行了分析。使用Bradford蛋白质测定法测量溶解的纳米颗粒来测定包封效率。使用SDS-PAGE验证从纳米颗粒释放的抗原的稳定性。为了评估纳米颗粒增强抗原呈递的假设,包括可溶性肿瘤裂解物、含纳米颗粒的肿瘤裂解物和对照纳米颗粒,通过评估T细胞与DC共培养后CD3 + T细胞刺激来评估纳米颗粒介导的肿瘤裂解物递送至DC的效率。
通过提高肿瘤裂解物的抗原浓度提高了包封率。然而,增加抗原浓度会降低包封效率。此外,初始蛋白质含量较高的纳米颗粒导致更大的累积释放。所有三名患者在再次刺激后释放了不同量的IFN-γ、IL-10、IL-12和IL-4。用裂解物脉冲DC刺激的T细胞诱导IFN-γ和IL-12产生大幅增加。我们证明含肿瘤裂解物的纳米颗粒可以像单独抗原一样诱导DC的成熟和激活。
PLGA纳米颗粒是蛋白质抗原递送的有吸引力的载体,可有效诱导DC的刺激和成熟,不仅可以增强抗原加工和免疫原性或改善抗原稳定性,还可以实现抗原的靶向递送和缓释。